Navigation Links
Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimer's Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
Date:4/16/2013

NEW YORK, April 16, 2013 /PRNewswire/ -- Exosome Diagnostics, a developer of biofluid-based molecular diagnostic products for use in personalized medicine, today announced data demonstrating exosome technology performance in clinical applications which will be presented at the International Society for Extracellular Vesicles 2013 (ISEV 2013) annual meeting, April 16-20, in Boston. The ISEV meeting is the preeminent international conference in the rapidly growing field of exosome and microvesicle research.

"The ability to deliver full-length, high quality mRNA and microRNA from biofluids is critical to development of new research tools and clinical grade in vitro diagnostic tests not subject to the limitations of tissue biopsy," said Dr. Johan Skog , chief science officer of Exosome Diagnostics. "Our Alzheimer's disease findings are especially pertinent to advancing a molecular diagnostic test capable of detecting CNS disorders years before the onset of clinical symptoms when therapeutic intervention could provide the most benefit."

Dr. Skog will give two oral presentations. The first is entitled "Characterization of Exosome RNA as a Tool for Molecular Diagnostics", and will be given at 9:30 a.m. EDT on April 16 during the Frye Halloran Educational Symposium. The latest data on Exosome Diagnostics' proprietary biofluid RNA capture technology for disease biomarkers in urine, blood and cerebrospinal fluid (CSF) will be presented. The second, to be given at 9:45 a.m. EDT on April 20, is entitled "The Use Of CSF Microvesicle RNA For Diagnosis Of Alzheimer's Disease". This  presentation describes differences in CSF exosome microRNA expression associated with Alzheimer's disease and patients with subjective memory complaints but no evidence of Alzheimer's disease. 

James McCullough , chief executive officer of Exosome, said, "We are committed to enabling the research community with high-performance exosome technology RNA isolation kits beginning in 2014 for biomarker discovery from fresh and frozen biofluids.  In addition, we are continuing to advance multi-center in vitro diagnostic development programs in genitourinary (GU) Oncology and CSN disorders."  

Exosome Diagnostics' proprietary technology provides access to a previously unexplored source of genetic information directly from diseased cell populations.  Cells throughout the body shed exosomes into fluids as a natural package delivery system to other cells.  Exosomes carry key genes (mRNA and miRNA transcript) responsible for commanding disease growth that can be accessed quickly and repeatedly from a biofluid for analysis on PCR or next-generation sequencing instruments.  Exosome technology has the potential to allow doctors, researchers and drug developers to take repeated, accurate genetic "snapshots" of disease for diagnostic and therapeutic use without the need for a surgical tissue biopsy.

Exosome Diagnostics will also be presenting a poster on an additional study:

Abstract #37, 8-5:30pm EDT, Wednesday, April 17th:  Utility of Urinary Exosomes/Microvesicles to Non-Invasively Analyze Gene Expression in Prostate Cancer

L.M. Russo , A.N. Scott , P. Motamedinia, K.L. Bate , N. Sadeghi, G. Salazar, M. Lipsky, J. Lin, G. Hruby, K.K. Badani , D.P Petrylak, J.M McKiernan

About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are packaged and shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, cell-specific nucleic acids. The Company's proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The Company is commercializing exosome technology products for use in both the life sciences and clinical settings. For more information, please visit www.exosomedx.com.

Exosome Contact:
James McCullough
Chief Executive Officer
Exosome Diagnostics
(646) 843-4949

Exosome Media Contact:
Robert Flamm , Ph.D.
Russo Partners
(212) 845-4226
robert.flamm@russopartnersllc.com


'/>"/>
SOURCE Exosome Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical (AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
2. Aethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
3. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
4. QBC Diagnostics Awarded GSA Contract
5. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
6. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
7. Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy
8. ZINO Society Targets Medical Devices, Healthcare IT and Diagnostics
9. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
10. Breakthrough Prostate Cancer Diagnostics
11. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... As health professionals work to improve their approach to ... is doing more than filling out a survey; in many cases health professionals and ... in health care and research on the importance of active engagement with patients and ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):